Evidence map›Paper›PMID 33860871›Full record

ArticleClinical autonomic research : official journal of the Clinical Autonomic Research Society2021

Autonomic dysfunction following COVID-19 infection: an early experience.

Kamal Shouman, Greg Vanichkachorn, William P Cheshire, Mariana D Suarez, Shahar Shelly, Guillaume J Lamotte, Paola Sandroni, Eduardo E Benarroch, Sarah E Berini, Jeremy K Cutsforth-Gregory and 4 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 1 pooled it
22.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 1 synthesis or guideline pooled it, 280 citations in OpenAlex.

  1. Pooled it
  2. An open trial of biofeedback for long COVID.Journal of psychosomatic research · 2024
    Trial
  3. Article
  4. Article
  5. Article
  6. Temporal patterns of neurological deterioration in COVID-19 survivors: a longitudinal cohort analysis of post-acute neurological sequelae.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  7. A case of seropositive autoimmune autonomic ganglionopathy treated with rituximab: Case report and review of the literature.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Autonomic dysfunction and quality of life in a cohort of neurology outpatients with post-acute sequelae of COVID-19, a two-year follow-up study.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Kamal ShoumanDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Greg VanichkachornPreventive, Occupational, and Aerospace Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
William P CheshireDepartment of Neurology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.
Mariana D SuarezDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Shahar ShellyDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Guillaume J LamotteDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Paola SandroniDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Eduardo E BenarrochDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Sarah E BeriniDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jeremy K Cutsforth-GregoryDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Elizabeth A CoonDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Michelle L MauermannDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Phillip A LowDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Wolfgang SingerDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. singer.wolfgang@mayo.edu.ORCID http://orcid.org/0000-0003-1263-6850
Mayo Clinic · USMayo Clinic in Florida · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
NCATS NIH HHS UL1 TR000135NIH HHS NS 926250NIH HHS UL1 TR000135
6 · The paper itself

Abstract

purposePost-COVID-19 syndrome is a poorly understood aspect of the current pandemic, with clinical features that overlap with symptoms of autonomic/small fiber dysfunction. An early systematic analysis of autonomic dysfunction following COVID-19 is lacking and may provide initial insights into the spectrum of this condition.

methodsWe conducted a retrospective review of all patients with confirmed history of COVID-19 infection referred for autonomic testing for symptoms concerning for para-/postinfectious autonomic dysfunction at Mayo Clinic Rochester or Jacksonville between March 2020 and January 2021.

resultsWe identified 27 patients fulfilling the search criteria. Symptoms developed between 0 and 122 days following the acute infection and included lightheadedness (93%), orthostatic headache (22%), syncope (11%), hyperhidrosis (11%), and burning pain (11%). Sudomotor function was abnormal in 36%, cardiovagal function in 27%, and cardiovascular adrenergic function in 7%. The most common clinical scenario was orthostatic symptoms without tachycardia or hypotension (41%); 22% of patients fulfilled the criteria for postural tachycardia syndrome (POTS), and 11% had borderline findings to support orthostatic intolerance. One patient each was diagnosed with autoimmune autonomic ganglionopathy, inappropriate sinus tachycardia, vasodepressor syncope, cough/vasovagal syncope, exacerbation of preexisting orthostatic hypotension, exacerbation of sensory and autonomic neuropathy, and exacerbation of small fiber neuropathy.

conclusionAbnormalities on autonomic testing were seen in the majority of patients but were mild in most cases. The most common finding was orthostatic intolerance, often without objective hemodynamic abnormalities on testing. Unmasking/exacerbation of preexisting conditions was seen. The temporal association between infection and autonomic symptoms implies a causal relationship, which however cannot be proven by this study.

Indexed as

AdultAgedAutonomic DysreflexiaAutonomic Fibers, PostganglionicAutonomic Nervous System DiseasesCOVID-19DizzinessFemaleHemodynamicsHumansMaleMiddle AgedNeurologic ExaminationOrthostatic IntolerancePost-Acute COVID-19 SyndromePostural Orthostatic Tachycardia SyndromeAutoimmune autonomic ganglionopathyAutonomic diseasesCOVID-19Orthostatic intolerancePostural orthostatic tachycardia syndrome

Identifiers

PMID33860871
PMCPMC8050227
OpenAlexW3152655454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.